Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical ...

The clinical-stage biopharmaceutical company reported that the trial met its primary endpoint, with up to 59.1% of participants achieving MASH resolution without worsening of fibrosis in an ...